Movement Alert|DexCom falls 5.01% in Regular Trading, recent post-earnings gains retreat despite strong Q3 results

Market Focus11-06

On November 6, DexCom fell 5.01% in Regular Trading, trading at $84.04, with turnover of $147 million.

The most relevant recent catalyst in public information is a movement alert indicating that the stock is giving back part of its earlier post-earnings advance, even though the company had reported better-than-expected third-quarter results, raised full-year revenue guidance, and saw a higher price target from Barclays.

In the third quarter, adjusted EPS was $0.73 versus the $0.67 consensus, while revenue reached $1.344 billion versus the $1.327 billion expectation. DexCom also lifted its full-year revenue guidance to $5.20 billion-$5.25 billion. Additional analyst commentary highlighted U.S. share gains, near-record global new-patient additions, and progress converting nearly half of the U.S. installed base to the 15-day G7 sensor by year-end, while Barclays raised its price target to $120 from $115.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment